AGM Chairman's Address & Presentation

For personal use only

25/11/21

EMvision Medical Devices Ltd

ACN 620 388 230

Level 10, 12 Creek Street, Brisbane Qld 4000

02 8667 5337 contact@emvision.com.au

AGM CHAIRMAN'S ADDRESS

& PRESENTATION

EMVision Medical Devices Limited (ASX: EMV) ("EMVision" or the "Company"), is pleased to provide the following Chairman's address and CEO Presentation to be made at the Company's 2021 Annual General Meeting at 12.30pm AEST today.

Chairman's Address

I am pleased to report that the EMVision team have delivered an important series of milestones this year including in the field of technology and commercial product development, the build of our 1st Generation portable brain scanner intended for commercialization and the significantly enhanced market awareness and recognition of our device through our strengthened collaboration with the Australian Stroke Alliance, which also delivered significant non-dilutive funding to accelerate our activities.

The successes over the last year, despite Covid-19, has been due to the quality of our teams, especially our product development team, research collaborators and The University of Queensland and the quality of our technology together with the enthusiasm and engagement we receive from clinicians, together helping us towards solving the huge unmet need in the area of stroke diagnosis and care.

Our technology is well on the way to revolutionizing the diagnosis, monitoring and treatment of stroke and other neurological conditions with the potential to save countless lives and greatly improve outcomes for patients.

Our vision is to meet this challenge and help overcome health inequity through our innovative neuroimaging technology that can provide point-of-care stroke diagnosis and monitoring, wherever the patient is, starting in the hospital, and in the future, in the back of the ambulance, enabling "golden hour" care.

Turning to EMV's balance sheet, we were pleased to secure $8m of non-dilutive staged grant funding via the Australian Stroke Alliance and Medical Research Future Fund during the year, further strengthening our financial position. $1.2 million of this grant funding has been received in the current quarter. We also anticipate the receipt of our FY21 R&D tax refund shortly and the balance of funds due under the CRC-P grant.

I would like to acknowledge the directors of EMVision who's extensive range of experience and expertise contributes significantly to the company's success and our hard working and very talented management team who are driving our Company forward.

Our business is in a strong position to capitalize on the enormous opportunity ahead and the board is confident in our management team's ability to execute against strategic priority and maximize shareholder value. I would like to thank all our shareholders for their ongoing support.

Shortly our CEO and Managing Director Dr Ron Weinberger, and his management team, will review the operational highlights for the year and the road ahead.

Authorised for release by the Board of the Company.

[ENDS]

For personal use only

For further information, media or investor enquiries, please contact:

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a $2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

ersonal use only

AGM - 2021

CEO & EXECUTIVE TEAM

PRESENTATION

ersonal use only